I will provide pharma due diligence and competitive intelligence
Translator, PPT Designer and SEO Writer
Informazioni su questo servizio
Need reliable pharmaceutical company research, drug pipeline analysis, or competitive intelligence?
I provide structured research for pharmaceutical, biotech, healthcare, and life sciences projects using publicly available and verifiable sources.
My research can cover:
- Company background and business profile
- Drug pipelines and development stages
- Clinical trials and key milestones
- Competitor and market landscape
- Partnerships, licensing, financing, and major events
- Public risk signals and recent developments
- China healthcare, pharmaceutical policy, reimbursement, regulatory, and market access context
- Clearly cited sources and research references
Reports are tailored to your research objective and can be delivered as a concise company snapshot, an in-depth intelligence report, or a comprehensive presentation.
Please message me before ordering if your project is highly specialized or requires a large number of companies or drugs.
This service is for research and business intelligence purposes only and does not constitute medical, legal, or investment advice.
Tipo di ricerca:
Qualitativo
Settore:
Medico e farmaceutico
•
Settore pubblico
•
Scienza
Il mio portfolio
FAQ
What information do you need to start the research?
Please provide the company or drug name, research objective, target market or country, key questions you want answered, and any preferred sources or report format. If you are unsure, I can help define the research scope before starting.
What sources do you use for pharmaceutical research?
I use publicly available and verifiable sources such as company filings and websites, regulatory databases, clinical trial registries, scientific publications, official policy documents, and reputable industry or news sources. Relevant sources are cited in the final report.
Can you research China pharmaceutical and healthcare policies?
Yes. I can research publicly available China healthcare and pharmaceutical policies, including regulatory updates, reimbursement, NRDL, volume-based procurement, market access, and relevant business implications.

